Skip to content
Search

Latest Stories

EU set to cut costs from duplication of medical tests, wider use of interoperable electronic health data

The European Commission wants to make health data easier to access for patients, medics, regulators and researchers in a bid to improve diagnoses, cut unnecessary costs from duplication of medical tests and boost medicine research, an EU document says.

The document which is being published today outlines the EU executive's plans for a European health data space which Brussels estimates would lead to large savings and economic gains of more than 10 billion euros in 10 years.


EU patients spend 1.4 billion euros every year on unnecessary medical images alone, the document said, estimating that one in 10 X-rays or ultrasound tests are not needed because they are usually duplications of existing valid images.

Electronic prescriptions

Wider use of easily accessible electronic prescriptions is also estimated to lead to large savings by reducing errors in dispensing medicines. Many states still use paper prescriptions.

The proliferation of unneeded tests and prescribed drugs is caused mostly by problems in accessing health data, because often health information is not accessible to patients themselves and hospitals only partly share data with each other.

"People cannot always easily access their health data electronically, and if they want to consult doctors in more than one hospital or medical centre, they often cannot share the data with other health professionals," the document said.

Interoperable health data

The EU commission believes it could address the problem by making data more accessible to patients through the creation of databases which are freely accessible online.

EU health commissioner Stella Kyriakides has said easier access to health data would also greatly help patients with serious conditions, such as cancer, by improving diagnoses.

Under the plan, healthcare providers would be required to produce electronic health data that are interoperable.

Data generated from patients' health records and wellness apps would be pooled in compatible formats and made accessible to patients, regulators and researchers under strict rules to protect privacy, the document says. Stronger cybersecurity is also planned.

The Commission estimates that easier access to anonymised health records for analysts and data professionals could lead to 5.4 billion euros in economic gains in a decade thanks to more effective research and cheaper drugs.

Another 5.5 billion euros in gains would come from savings for patients and healthcare providers, and from "faster growth of the digital health and wellness applications markets".

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less